Jacob Schmelz, MD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Jacob Schmelz, MD
Jacob Schmelz, MD, is an assistant professor of hematology at The University of Texas at San Antonio and associate program director for the Hematology-Oncology Fellowship program. Dr. Schmelz specializes in blood disorders, with clinical interests including bleeding disorders, vascular anomalies and blood clots such as deep vein thrombosis and pulmonary embolism. He practices at Mays Cancer Center and the South Texas Center for Bleeding Disorders at UT Health Gateway.
Dr. Schmelz earned his undergraduate degree in physics from The University of Texas at Austin and his medical degree from McGovern Medical School at UTHealth Houston. He completed his internal medicine residency and hematology fellowship training at UT Health San Antonio, where he also served as chief resident for research and education.
Gender
- Male
Languages Spoken
- English
- Spanish
-
Credentials
Credentials
Positions
- Assistant Professor, Division of Hematology and Oncology, The University of Texas at San Antonio
- Associate Program Director, Medical Oncology and Hematology Fellowship Program
- Hematologist, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine, Internal Medicine
Education
- Medical School: McGovern Medical School at UTHealth Houston, Houston, Texas
- Fellowship: Hematology, The University of Texas at San Antonio Health Science Center, San Antonio, Texas
- Residency: Internal Medicine, The University of Texas at San Antonio Health Science Center, San Antonio, Texas
- Undergraduate: Physics, The University of Texas at Austin, Austin, Texas
- Locations & Contact
-
Research & Publications
Research & Publications
A national analysis of Burkitt lymphoma in the Hispanic community.
Alhaj S, Schmelz J, Liu Qianqian, Michalek J, Diaz Duque AE.
J Clin Onc. 2023;16_suppl: e18818-e18818. doi: 10.1200/JCO.2023.41.16_suppl.e11818.
Chimeric antigen receptor T-cell therapy’s role in antiphospholipid syndrome: a case report.
Schmelz J, Navsaria L, Goswamy R, Chuang H, Miranda R, Lee HJ.
Br J Haematol. 2020;188(3):e5-e8. doi: 10.1111/bjh.16266.
A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
Lee HJ, Schmelz J, Cramer F, Romaguera J, Badillo M, Wang M.
Br J Haematol. 2020;188(6):e94-98. doi: 10.1111/bjh.16378.
-
Clinical Trials
Clinical Trials
No Clinical Trials